BDRX
NASDAQBiodexa Pharmaceuticals plc American Depositary Shs
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.06-1.18 (-36.42%)
2026-04-142026-07-17
News · 26 weeks56+600%
2026-01-182026-07-12
Mix1990d
- SEC Filings13(68%)
- Other5(26%)
- Offering1(5%)
Latest news
25 items- SECSEC Form F-1 filed by Biodexa Pharmaceuticals plc American Depositary ShsF-1 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B5 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B5 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRResult of Annual General MeetingJune 30, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively. Ordinary resolution 8 and special resolution 10 failed to pass. Because resolution 11 was contingent on the passing of resolution 8, resolution 11 also failed to pass. ENDS About Biodexa P
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and WarrantsJune 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a $0.8 million registered offering (the "Registered Offering"), a $1.0 million concurrent private placement (the "Private Offering") and a $1.7 million warrant inducement (the "Warrant Inducement" and, together with the Registered Offering and the Private Offering, the "Offerings") utilizing existin
- PRApproval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta ProgressJune 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAPandUpdate on Serenta Progress Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has received approval from Health Canada to expand its registrational Phase 3 trial in familial adenomatous polyposis ("FAP") into Canada. The Phase 3 study, branded Serenta, is already up and running in a total of 29 active recruiting clinical centers spread across the US and five countries in Europe. Canada is expected to ad
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRPostponement and Re-scheduling of Annual General MeetingJune 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that its Annual General Meeting ("AGM") scheduled for 11.00am BST today was adjourned due to lack of a quorum. In accordance with the Company's articles of association, the AGM cannot be reconvened for 10 clear days. Accordingly, the AGM has been re-scheduled for 11.00am BST on June 30, 2026 at the Company's offices at
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biodexa Pharmaceuticals plc American Depositary ShsSCHEDULE 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa issues letter to ShareholdersMay 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company's share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder's rights. "Dear Shareholder, Annual General Meeting Proposals to Reorganize Share Capital Without Affecting Shareholder's Rights or Number of ADSs Outstanding With this lette
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
BDRX FAQ
5 questionsWhere does BDRX stock trade?
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is listed on NASDAQ.What sector and industry is BDRX in?
Biodexa Pharmaceuticals plc American Depositary Shs operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BDRX?
Biodexa Pharmaceuticals plc American Depositary Shs has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $800.00 price target on 2024-02-08. Recent price targets cluster around $800.00.What companies are similar to BDRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BDRX side-by-side with any of them on Quantisnow.How can I track BDRX on Quantisnow?
Quantisnow aggregates Biodexa Pharmaceuticals plc American Depositary Shs's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDRX to receive live email and push alerts on every new disclosure.